Department of Thyroid and Breast Surgery, Songgang People's Hospital of Baoan District in Shenzhen, Shenzhen, China.
Eur Rev Med Pharmacol Sci. 2021 Jan;25(1):154-160. doi: 10.26355/eurrev_202101_24379.
Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer (BC) with poor prognosis. Identification of reliable biomarkers for predicting prognosis of TNBC contributes significantly to improve the clinical outcome and disease management. Long non-coding RNAs (LncRNAs) have been demonstrated to play a critical role in tumorigenesis of TNBC. In this study, we aimed to investigate the prognostic significance of serum exosomal lncRNA small ubiquitin-like modifier 1 pseudogene 3 (SUMO1P3) in TNBC.
The expression level and clinical significance of tissue lncRNA SUMO1P3 in BC were analyzed using the public The Cancer Genome Atlas (TCGA) dataset. Then,A. Na-er, Y.-Y. Xu, Y.-H. Liu, Y.-J. Gan the serum exosomal lncRNA SUMO1P3 levels were examined in patients with TNBC, patients with non-TNBC, patients with benign breast disease and healthy controls using the quantitative real-time PCR. The potential clinical significance of serum exosomal lncRNA SUMO1P3 was further evaluated.
Based on the TCGA data, tissue lncRNA SUMO1P3 was upregulated in BC tissues, and its upregulation was significantly correlated with poor survival. Our findings showed that the expression level of serum exosomal lncRNA SUMO1P3 was significantly higher in patients with TNBC compared to patients with non-TNBC, patients with benign breast disease and healthy controls. In addition, serum exosomal lncRNA SUMO1P3 was closely correlated with lymphovascular invasion, lymph node metastasis and histological grade. The serum exosomal lncRNA SUMO1P3 levels were markedly decreased in chemosensitive cases, while not in the chemoresistance cases. Moreover, patients in the high serum exosomal lncRNA SUMO1P3 group had worse overall survival than the patients in the low serum exosomal lncRNA SUMO1P3 group. The multivariate analysis showed that serum exosomal lncRNA SUMO1P3 was an independent prognostic factor for TNBC.
Collectively, serum exosomal lncRNA SUMO1P3 might be a reliable and robust prognostic biomarker for TNBC.
三阴性乳腺癌（TNBC）是一种预后不良的侵袭性乳腺癌亚型。鉴定可靠的生物标志物来预测 TNBC 的预后有助于改善临床结果和疾病管理。长链非编码 RNA（lncRNA）已被证明在 TNBC 的肿瘤发生中起关键作用。在本研究中，我们旨在研究血清外泌体 lncRNA 小泛素样修饰因子 1 假基因 3（SUMO1P3）在 TNBC 中的预后意义。
使用公共的癌症基因组图谱（TCGA）数据集分析组织 lncRNA SUMO1P3 在 BC 中的表达水平和临床意义。然后，使用定量实时 PCR 检测 TNBC 患者、非 TNBC 患者、良性乳腺疾病患者和健康对照者的血清外泌体 lncRNA SUMO1P3 水平。进一步评估血清外泌体 lncRNA SUMO1P3 的潜在临床意义。
基于 TCGA 数据，组织 lncRNA SUMO1P3 在 BC 组织中上调，其上调与不良预后显著相关。我们的研究结果表明，与非 TNBC 患者、良性乳腺疾病患者和健康对照者相比，TNBC 患者血清外泌体 lncRNA SUMO1P3 的表达水平显著升高。此外，血清外泌体 lncRNA SUMO1P3 与淋巴血管侵犯、淋巴结转移和组织学分级密切相关。在化疗敏感病例中，血清外泌体 lncRNA SUMO1P3 水平明显降低，而在化疗耐药病例中则不然。此外，血清外泌体 lncRNA SUMO1P3 水平较高的患者总生存期明显差于血清外泌体 lncRNA SUMO1P3 水平较低的患者。多变量分析显示，血清外泌体 lncRNA SUMO1P3 是 TNBC 的独立预后因素。
总之，血清外泌体 lncRNA SUMO1P3 可能是 TNBC 可靠而稳健的预后生物标志物。
